SEC Form 4 · accession 0001193125-26-383697
AN2 Therapeutics, Inc. · ANTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sarah Joanne Williams
Officer — Principal Accounting Officer
Period of report
Sep 1, 2026
Accepted (ET)
Sep 4, 2026 · 4:25 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001880438
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 1, 2026 | S | 272 | $5.53 | D | 66,311 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on August 28, 2026.
- F2Includes (a) 48,375 RSUs which vest as follows: 1/4th of the shares vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2026, and the balance of (b) 10,938 RSUs which vest as follows: 1/4th of the RSUs vests in substantially equal installments annually (rounded down to the nearest whole number of shares) over four years from January 1, 2025, and (c) 11,850 RSUs which vest as follows: 1/16th of the RSUs vests in substantially equal installments quarterly (rounded down to the nearest whole number of shares) over four years from May 28, 2024, in each case subject to the Reporting Person's continuous service through each applicable vesting date. A total of 4,038 shares from the aggregate number of the RSUs issued under (b) and (c) above were sold to cover taxes and a total of 814 shares were sold on the open market.